



# The 9th International Electronic Conference on Medicinal Chemistry (ECMC 2023)

01–30 November 2023 | Online

## Adarotene-related retinoids as potential antimicrobial agents against multidrug-resistant gram-positive strains

Chaired by **Dr. Alfredo Berzal-Herranz**  
and **Prof. Dr. Maria Emília Sousa**



*pharmaceuticals*




**Salvatore Princiotto<sup>1,\*</sup>, Loana Musso<sup>1</sup>, Francesca Sacchi<sup>1</sup>, Lucia Magnani<sup>1</sup>, Maria Luisa Mangoni<sup>2</sup>, Claudio Pisano<sup>3</sup>, and S. Dallavalle<sup>1</sup>**

<sup>1</sup> Department of Food, Environmental and Nutritional Sciences (DEFENS), University of Milan, via Celoria, 2, 20133 Milan, Italy;

<sup>2</sup> Department of Biochemical Sciences "A. Rossi Fanelli", Faculty of Pharmacy and Medicine, Sapienza University of Rome, Piazzale Aldo Moro, 5, 00185, Roma, Italy


<sup>3</sup> Preclinical Research & Biotech Development, Special Product's Line, Via Fratta Rotonda Vado Largo, 1, 03012 Anagni (FR), Italy

\* Corresponding author: [salvatore.princiotto@unimi.it](mailto:salvatore.princiotto@unimi.it)






# Adarotene-related retinoids as potential antimicrobial agents against multidrug-resistant gram-positive strains





Multidrug-resistant (MDR) pathogens are severely impacting our ability to successfully treat common infections. As a consequence, bacterial resistance to antimicrobial drugs represents one of the most impelling topics in medicinal chemistry. In recent years we have focused our efforts on the investigation of a panel of adarotene-related synthetic retinoids showing, together with favorable MICs, a detectable bactericidal effect on *S. aureus* and *E. faecalis* (including some MDR strains).<sup>1</sup> Based on these promising results, a small collection of adarotene related retinoids was prepared. Chemical modifications were performed on the carboxylic group and the double bond of the cinnamic portion, as well as polar substituents were introduced on ring A and ring B, in order to evaluate the potential structural determinants necessary to exert antibiotic activity (Figure 1). Overall, the results showed that compounds with a very good activity profile can be obtained by modulating the pattern of substitution on the adarotene moiety. Moreover, the shape and geometry of the molecules, together with the presence of key polar groups on the biphenyl backbone, could play a major role for the antimicrobial effect on resistant strains.



**Figure 1:** Structure of adarotene and suitable modifications on its scaffold.


**References:**

[1] S. Princiotta, S. Mazzini, L. Musso, F. Arena, S. Dallavalle, and C. Pisano, *Antibiotics* **2021**, *10*, 126.







## Retinoid-related molecules (RRMs)




CD437



CD1530



adapalene



adapalene

- Pro-apoptotic activity on solid tumors and leukemia
- Evidences of antimicrobial activity (Kim et al. *Nature* **556**, 103–107 (2018))

## LETTER

doi:10.1038/nature26157


### A new class of synthetic retinoid antibiotics effective against bacterial persisters

Wooseong Kim<sup>1</sup>, Wenpeng Zhu<sup>2</sup>, Gabriel Lambert Hendricks<sup>1</sup>, Daria Van Tyne<sup>3,4</sup>, Andrew D. Steele<sup>5,6</sup>, Colleen E. Keohane<sup>5,6</sup>, Nico Fricke<sup>2</sup>, Annie L. Conery<sup>7,8</sup>, Steven Shen<sup>1</sup>, Wen Pan<sup>1</sup>, Kiho Lee<sup>1</sup>, Rajmohan Rajamuthiah<sup>1</sup>, Beth Burgwyn Fuchs<sup>1</sup>, Petia M. Vlahovska<sup>9</sup>, William M. Wuest<sup>5,6</sup>, Michael S. Gilmore<sup>3,4</sup>, Huajian Gao<sup>2</sup>, Frederick M. Ausubel<sup>7,8</sup> & Eleftherios Mylonakis<sup>1</sup>







## Retinoid-related molecules (RRMs)




CD437



CD1530





adarotene



adapalene

- Pro-apoptotic activity on solid tumors and leukemia
- Evidences of antimicrobial activity (Kim et al. *Nature* **556**, 103–107 (2018))











## Biological activity evaluation

cpd	IC <sub>50</sub> (μM) <sup>a</sup>	MIC (μg/mL)	
		<i>S. aureus</i> Strain 1	<i>E. faecalis</i> Strain 1
<b>Adarotene</b>	0.23±0.08	8	1
<b>1</b>	30	64	>256
<b>2</b>	>10	256	128
<b>3</b>	7.8±0.7	32	128
<b>4</b>	8.3±1.4	128	32
<b>5</b>	1.1±0.6	64	>256
<b>6</b>	6.6±0.5	>256	>256
<b>7</b>	>3	4	4
<b>8</b>	7.19±1.27	2	1
<b>9</b>	>10	2	1
<b>10</b>	48.42±0.88	16	16
<b>11</b>	0.52±0.07	16	8
<b>12</b>	0.23±0.07	4	2
<b>13</b>	1.24±0.07	8	4
<b>14</b>	>10	8	4
<b>15</b>	1.64±0.03	64	64
<b>16</b>	>10	4	2
<b>17</b>	>10	4	8
<b>18</b>	>10	128	128
<b>19</b>	>10	32	32
<b>20</b>	3.2±0.2	2	8




cpd	MIC (μg/mL)			
	<i>S. aureus</i> ATCC 25923	<i>S. aureus</i> Strain 2	<i>E. faecalis</i> ATCC 51299	<i>E. faecalis</i> Strain 2
<b>Adarotene</b>	8	4	2	4
<b>2</b>	256	256	64	128
<b>16</b>	2	2	2	2
<b>17</b>	2	4	8	8



<sup>a</sup> tested IGROV-1 cancer cell line




## New adarotene analogues






## Structural modifications on acidic and phenolic portions



a) adamantan-1-ol,  $\text{H}_2\text{SO}_4/\text{AcOH}$ ; b)  $\text{Tf}_2\text{O}$ , Py; c) bis(pinacolato)diboron, KOAc,  $\text{PdCl}_2(\text{dppf})$ ; d) **22**,  $\text{Pd}(\text{PPh}_3)_4$ ,  $\text{Na}_2\text{CO}_3$  2 M, DME/EtOH 9:1; e) methyl acrylate, TOTP,  $\text{Pd}(\text{OAc})_2$ ,  $\text{Et}_3\text{N}$ ; f) LiOH  $\text{H}_2\text{O}$ , THF/ $\text{H}_2\text{O}$ ; g) CDI, DMF; h) WSC, HOBT, 1,2-phenylenediamine,  $\text{CH}_3\text{CN}/\text{THF}$ ; i) 4-bromobutyl acetate,  $\text{K}_2\text{CO}_3$ , DMF; j) i. 0.7N NaOH,  $\text{CH}_3\text{OH}$ , reflux; ii. 1M HCl; k) acrylonitrile, tri(*o*-tolyl)phosphine,  $\text{Pd}(\text{OAc})_2$ ; l) acetic anhydride, PTSA




## Substitutions on ring A



a) adamantan-1-ol,  $H_2SO_4/AcOH$ ; b) bis(pinacolato)diboron,  $PdCl_2(dppf)$ ,  $KOAc$ , methyl *p*-bromocinnamate,  $Na_2CO_3$  2 M and  $PdCl_2(dppf)$ ; c)  $LiOH$   $THF/H_2O$ ; d)  $(CH_2)_n, SnCl_4, 2,6$ -lutidine, toluene; e)  $Pd(OAc)_2$ , tri(*o*-tolyl)phosphine,  $Et_3N$ , *tert*-butyl acrylate; f) *O*-*t*-butyl hydroxylamine hydrochloride, pyridine,  $EtOH$ , reflux; g)  $TFA$ , dry  $CH_2Cl_2$




## Substitutions on ring B



a) Methyl acrylate, Pd(OAc)<sub>2</sub>, TOTP, TEA; b) C<sub>6</sub>H<sub>5</sub>(SO<sub>2</sub>CF<sub>3</sub>)<sub>2</sub>, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>; c) TBDMSCl, Et<sub>3</sub>N, DMAP, DMF; d) bis(pinacolato)diboron, KOAc, PdCl<sub>2</sub>(dppf), **27**, Na<sub>2</sub>CO<sub>3</sub>; e) LiOH H<sub>2</sub>O, THF/H<sub>2</sub>O, 1:1; f) *t*-BuONH<sub>2</sub>·HCl (**16**) or MeONH<sub>2</sub>·HCl (**17**) or NH<sub>2</sub>OCH<sub>2</sub>COOH·1/2 HCl (**18**) or AlONH<sub>2</sub>·HCl (**45**) or BnONH<sub>2</sub>·HCl (**46**) py, EtOH, reflux; g) LiOH·H<sub>2</sub>O THF/H<sub>2</sub>O 1:1; h) pyridinium tribromide, CH<sub>2</sub>Cl<sub>2</sub>; i) *t*-BuONH<sub>2</sub>·HCl, EtOH, pyridine, reflux; j) KOH, isopropanol, reflux



## Substitutions on the cinnamic portion






a)  $\text{PdCl}_2(\text{dppf})\cdot\text{CH}_2\text{Cl}_2$ , KOAc, diboro-bis-pinacolate, dioxane; b) **22**,  $\text{Pd}(\text{PPh}_3)_4$ ,  $\text{Na}_2\text{CO}_3$  2 M, DME/EtOH 9:1; c) methyl acrylate, tri(*o*-tolyl)phosphine,  $\text{Pd}(\text{OAc})_2$ ,  $\text{Et}_3\text{N}$ ; d)  $\text{LiAlH}_4$ , THF; e) i.  $\text{CuI}$ ,  $\text{PdCl}_2(\text{Ph}_3\text{P})_2$ , diisopropylamine,  $\text{Et}_3\text{N}$ ; ii. propargyl alcohol; f) 4-Formylbenzeneboronic acid,  $\text{Pd}(\text{Ph}_3\text{P})_4$ ,  $\text{Na}_2\text{CO}_3$ , toluene; g)  $\text{NaBH}_4$  in MeOH; h)  $\text{KMnO}_4$ ,  $\text{H}_2\text{O}$ /acetone; i) TBDMSCl,  $\text{Et}_3\text{N}$ , DMAP, DMF; j)  $\text{Ph}_3\text{PdC}(\text{CH}_3)\text{COOEt}/\text{CHCl}_3/\text{BuLi}/\text{THF}$  (**7**) or  $\text{EtOCOCHFPO}(\text{OEt})_2/\text{BuLi}/\text{THF}$  (**8**) or methyl cyanoacetate,  $\beta$ -alanine, EtOH; k) LiOH  $\text{H}_2\text{O}$ , DMF




## Biological activity evaluation

cpd	MIC ( $\mu\text{M}$ )	
	<i>S. aureus</i>	<i>E. coli</i>
	ATCC 25923	ATCC 25922
Adarotene	21	-
16	4	>128
30	>128	>128
31	>128	>128
32	>128	>128
33	64	>128
34	16	>128
35	64	n.d.
36	16	>128
37	4	>128
38	>128	>128
39	16	>128
40	8	>128
41	4	>128
42	>128	>128
43	>128	>128
44	>128	>128
45	4	>128
46	8	>128
47	32	>128
48	32	>128
49	>128	>128
50	>128	>128
51	128	>128
52	>128	>128
53	8	>128







Strain	Resistance profile	MIC ( $\mu\text{M}$ )
<i>S. epidermidis</i> ATCC 12228	-	4
<i>S. aureus</i> ATCC 43300	MET - OXA	2
<i>S. aureus</i> #2	BEN - CLI - DAP - ERI - LEV - OXA - VAN	4
<i>S. aureus</i> 13667073	AZI - BEN - CIP - CLI - ERI - LEV - MOX - OXA	4
<i>S. aureus</i> 02216108	BEN - CIP - LEV - MOX - OXA	2









# Molecular dynamic studies





# Molecular dynamic studies







# Pharmacokinetic studies and co-administration


Compound 16

Cell line	% Survival
-----------	------------

HaCaT	109
Fibroblasts	88
AoSMC	99
HUVEC	88




**A** *S. aureus* ATCC 25923



- ✱ Ctrl
- 16 [2 µM]
- RIF [0.125 µg/mL]
- RIF [0.06 µg/mL]
- RIF [0.03 µg/mL]
- - RIF [0.125 µg/mL] + 16 [2 µM]
- - RIF [0.06 µg/mL] + 16 [2 µM]
- - RIF [0.03 µg/mL] + 16 [2 µM]

**B** *S. aureus* #2 MDR



- ✱ Ctrl
- 16 [2 µM]
- RIF [0.03 µg/mL]
- RIF [0.015 µg/mL]
- RIF [0.0075 µg/mL]
- - RIF [0.03 µg/mL] + 16 [2 µM]
- - RIF [0.015 µg/mL] + 16 [2 µM]
- - RIF [0.0075 µg/mL] + 16 [2 µM]



## Conclusions and future perspectives

- A collection of variously substituted adarotene derivatives has been prepared
- Preliminary structure-activity relationship studies indicated that:
  - the substitution of phenolic OH and carboxylic acid decreases the antimicrobial activity;
  - the functionalization of the cinnamic portion is tolerated;
  - the introduction of substituents on ring B considerably enhances the activity.
- Oxime **16** resulted as the most promising compound on several MDR strains of Gram + bacteria
- Suitable substituents are under study for the obtainment of compounds active on MDR Gram – bacteria





## Acknowledgements

- Prof. Sabrina Dallavalle
- Dr. Loana Musso
  
- Francesca Sacchi
- Lucia Magnani
- Luca Pozzi
  
- Dr. Stefania Mazzini
  
- Prof. Maria Luisa Mangoni
- Dr. Claudio Pisano
- Prof. Mattia Mori
  
- Project fundings:  
Special Product's Line



*Special Product's Line* S.p.A.  
Industria Farmaceutica

